Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00715611 · ClinicalTrials.gov registry record · Phase 2
Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
A Phase 2 study of Mesothelioma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
- 12
- Study locations
NCT00715611: Active Phase 2 study of Mesothelioma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00715611 is a Phase 2 study of Mesothelioma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 65 participants, below the 197-participant average among 46 other Mesothelioma trials with a reported enrollment target (67% lower). The trial reports 12 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00715611, a Phase 2 study of Mesothelioma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
- 12
- Study locations
Study Summary
For patients with this type of cancer, the standard of care is treatment with chemotherapy. Radiation therapy is typically not used. This is because radiation to the entire lining of the lung has many side effects that are often severe including damage to the lung (pneumonitis). There is a new radiation technique using Intensity Modulated Radiation Therapy (IMRT) that has been shown to reduce many of the side effects of standard radiation therapy. This type of radiation therapy specifically targets the lining of the lung, where you have your cancer, and reduces the risk of damaging the lung itself. The purpose of this study is to test the safety and implementation of standard pleurectomy/decortication (removal of the surface lining of the lung) and standard chemotherapy followed by IMRT performed at other centers. Patients will undergo pleurectomy/decortication chemotherapy and hemithoracic pleural IMRT to the pleura in patients with malignant pleural mesothelioma.
Primary Outcome
Grade 3 pneumonitis is defined as symptomatic, interfering with ADL's and requiring oxygen support as defined by the NCI Common Terminology Criteria (CTC) version 4.0 for toxicity and Adverse Event reporting.
Conditions Studied
Interventions
- RADIATION Intensity Modulated Radiation Therapy
- PROCEDURE Pleurectomy/Decortication
- DRUG pemetrexed and cisplatin or carboplatin
Study Locations (12)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack - Commack
- Memoral Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering at Rockville Center, NY - Rockville Centre
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering at Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Florida
- Moffitt Cancer Center - Tampa
Massachusetts
- Brigham and Women's Hospital - Boston
Minnesota
- Mayo Clinic Cancer Center - Rochester
Texas
- Md Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2008-10-11 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
What the registry record for NCT00715611 still lists
NCT00715611 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 197-participant average among 46 other Mesothelioma trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Mesothelioma appearing as the primary indexed condition, and to 3 interventions - of which Intensity Modulated Radiation Therapy is the first listed.
NCT00715611 lists 12 locations in 6 states (New York, New Jersey, Florida).
Frequently Asked Questions
What is clinical trial NCT00715611 about?
NCT00715611 is a clinical study titled "Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma". For patients with this type of cancer, the standard of care is treatment with chemotherapy. Radiation therapy is typically not used. This is because radiation to the entire lining of the lung has many side effects that are often severe including damage to the lung (pneumonitis). There is a new radia...
What is the current status of trial NCT00715611?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2008-10-11. Estimated completion is 2026-07.
What conditions does trial NCT00715611 study?
This clinical trial studies the following conditions: Mesothelioma.
What interventions are being tested in trial NCT00715611?
The interventions under investigation include: Intensity Modulated Radiation Therapy (RADIATION), Pleurectomy/Decortication (PROCEDURE), pemetrexed and cisplatin or carboplatin (DRUG).
Who is sponsoring clinical trial NCT00715611?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00715611 being conducted?
This trial has 12 study locations across Florida, Massachusetts, Minnesota, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00715611's enrollment target sits among peer trials
65 28th of 46 higher than 19 of 46 other Mesothelioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mesothelioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Sacituzumab Govitecan in People With Mesothelioma
RECRUITING · Phase 2
-
Olaparib in Patients With HRD Malignant Mesothelioma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI
RECRUITING · Phase 2
-
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
RECRUITING · Phase 2
-
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI